Medtide

Medtide P/B

The P/B (Price-to-Book Ratio) of Medtide (3880.HK) as of Oct 16, 2026 is 2.08. In the previous year, P/B (Price-to-Book Ratio) was 10.34 — a change of -79.89% (lower).

P/B

2.08

YoY

-79.89%

Last updated:

P/B (Price-to-Book Ratio) of Medtide is 2025 2.08 . P/B (Price-to-Book Ratio) of Medtide was 2024 10.34 . It decreases by -79.89% lower compared to the previous year.

The Medtide P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2021
31.36 CNY
Jan 1, 2022
16.28 CNY
Jan 1, 2023
12.99 CNY
Jan 1, 2024
10.34 CNY
Jan 1, 2025
2.08 CNY
The Medtide P/B history
YEARP/BYoY
2.08-79.89%
10.34-20.35%
12.99-20.25%
16.28-48.07%
31.36—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medtide Stock analysis

What does Medtide do? Medtide Inc, listed on the Hong Kong Stock Exchange under ticker 3880.HK, is a life sciences company headquartered in Hangzhou, China. The company, which has 522 full-time employees, specializes in peptide-focused contract research, development, and manufacturing services. Medtide provides contract research organization (CRO) services, including peptide new chemical entity (NCE) discovery and synthesis, as well as contract development and manufacturing organization (CDMO) services covering peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The company's primary focus is on delivering active pharmaceutical ingredients (APIs) rather than finished drug products. Medtide also offers peptide drug development, production, and CMC filing support services to its clients. The firm serves both domestic and international markets, operating across multiple regions. Medtide's initial public offering (IPO) is scheduled for June 30, 2025, as indicated by its IPO date. The company's website is http://medtideinc.com, where further information about its services and operations can be found. Medtide Inc. operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry, reflecting its specialized role in the pharmaceutical and biotechnology fields. The company's business model centers on providing comprehensive solutions for peptide-based drug development and manufacturing, targeting clients seeking expertise in this niche area of pharmaceutical services. Medtide is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medtide stock

P/B (Price-to-Book Ratio) of Medtide is 2.08 in 2025.

P/B (Price-to-Book Ratio) of Medtide changed from 10.34 to 2.08, representing a -79.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Medtide since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Medtide with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Medtide

All Key Metrics — Medtide